# A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

> **NCT03222609** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 191 (actual)

## Conditions studied

- Myelofibrosis (MF)

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Navitoclax

## Key facts

- **NCT ID:** NCT03222609
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-31
- **Primary completion:** 2022-03-28
- **Final completion:** 2025-01-29
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222609, "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03222609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*